Daiichi Sankyo Signs Research and Commercial Agreement with BioWa and Lonza

Lonza says that Daiichi Sankyo (Tokyo) has signed a research and commercial agreement with biotech company BioWa (Princeton, NJ), a subsidiary of Kyowa Hakko Kirin (Tokyo), and Lonza, to use their Potelligent CHOK1SV cell line for the development and production of recombinant antibodies. Potelligent CHOK1SV is a new host cell line for manufacturing recombinant antibodies that combines BioWa’s engineered glycosylation Potelligent technology with Lonza’s GS Gene Expression System, which includes the cell line CHOK1SV. Potelligent CHOK1SV has been chosen...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers